New Microbes and New Infections (Jul 2015)
The global threat of antimicrobial resistance: science for intervention
- I. Roca,
- M. Akova,
- F. Baquero,
- J. Carlet,
- M. Cavaleri,
- S. Coenen,
- J. Cohen,
- D. Findlay,
- I. Gyssens,
- O.E. Heure,
- G. Kahlmeter,
- H. Kruse,
- R. Laxminarayan,
- E. Liébana,
- L. López-Cerero,
- A. MacGowan,
- M. Martins,
- J. Rodríguez-Baño,
- J.-M. Rolain,
- C. Segovia,
- B. Sigauque,
- E. Tacconelli,
- E. Wellington,
- J. Vila
Affiliations
- I. Roca
- ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
- M. Akova
- Department of Medicine, Section of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey
- F. Baquero
- Department of Microbiology at the Ramón y Cajal University Hospital, Ramón y Cajal Institute for Health Research (IRYCIS), Division for Research in Microbial Biology and Evolution, CIBERESP, Madrid, Spain
- J. Carlet
- Fondation Hôpital St, Joseph, Paris, France and World Alliance Against Antibiotic Resistance (WAAAR), Creteil, France
- M. Cavaleri
- European Medicines Agency (EMA), London, UK
- S. Coenen
- Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- J. Cohen
- Brighton and Sussex Medical School, Brighton, UK
- D. Findlay
- Global Commercial Lead, GlaxoSmithKline (GSK), London, UK
- I. Gyssens
- Department of Medicine, Radboud University Medical Center and Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
- O.E. Heure
- European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
- G. Kahlmeter
- Clinical Microbiology, Central Hospital, Växjö, Sweden
- H. Kruse
- WHO Regional Office for Europe, UN City, Marmorvej, Copenhagen, Denmark
- R. Laxminarayan
- Center for Disease Dynamics, Economics and Policy, Washington, DC, USA
- E. Liébana
- Scientific Unit on Biological Hazards, European Food Safety Authority (EFSA), Parma, Italy
- L. López-Cerero
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain
- A. MacGowan
- Department of Medical Microbiology, Southmead Hospital, Bristol, UK
- M. Martins
- School of Public Health, Physiotherapy and Population Science, UCD Centre for Food and Safety, Molecular Innovation and Drug Discovery, University College Dublin, Dublin, Ireland
- J. Rodríguez-Baño
- Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, and Departamento de Medicina, Universidad de Sevilla, Seville, Spain
- J.-M. Rolain
- Aix-Marseille Université, Unité de Recherche en Maladies Infectieuses et Tropicales Emergentes (URMITE), Inserm, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, and APHM, CHU Timone, Pôle Infectieux, Marseille, France
- C. Segovia
- Instituto de Salud Carlos III, ISCIII, Madrid, Spain
- B. Sigauque
- Centro de Investigação em Saúde da Manhiça and Instituto Nacional de Saúde/Ministério de Saúde, Maputo, Mozambique
- E. Tacconelli
- Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Tübingen, Germany
- E. Wellington
- School of Life Sciences, University of Warwick, Coventry, UK
- J. Vila
- ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic—Universitat de Barcelona, Barcelona, Spain
- DOI
- https://doi.org/10.1016/j.nmni.2015.02.007
- Journal volume & issue
-
Vol. 6,
no. C
pp. 22 – 29
Abstract
In the last decade we have witnessed a dramatic increase in the proportion and absolute number of bacterial pathogens resistant to multiple antibacterial agents. Multidrug-resistant bacteria are currently considered as an emergent global disease and a major public health problem. The B-Debate meeting brought together renowned experts representing the main stakeholders (i.e. policy makers, public health authorities, regulatory agencies, pharmaceutical companies and the scientific community at large) to review the global threat of antibiotic resistance and come up with a coordinated set of strategies to fight antimicrobial resistance in a multifaceted approach. We summarize the views of the B-Debate participants regarding the current situation of antimicrobial resistance in animals and the food chain, within the community and the healthcare setting as well as the role of the environment and the development of novel diagnostic and therapeutic strategies, providing expert recommendations to tackle the global threat of antimicrobial resistance.
Keywords
- Antibiotic consumption
- antibiotic resistance
- antibiotic stewardship
- antibiotics as growth promoters
- drug discovery
- infection control measures
- multidrug resistant bacteria
- self-medication
- surveillance
- wastewater treatment plants
